HCPCS code S0187 – Tamoxifen citrate oral tablet

Key takeaways

HCPCS Code S0187 describes tamoxifen citrate, oral, 10 mg, and each billing unit equals one 10 mg tablet.

Medicare Part B rejects S codes, so Medicare patients get tamoxifen through Part D, billed by the pharmacy under the NDC.

A missing or invalid NDC and a wrong unit count are the two leading causes of S0187 denials.

No modifier is standard for S0187, so add KX or GY only where a payer’s own policy asks for it.

Pabau, the practice management platform we build, submits claims through a clearinghouse and tracks their status, while your team still enters the NDC and units.

HCPCS Code S0187: Official descriptor and key details

HCPCS Code S0187 is the Level II code for tamoxifen citrate, oral, 10 mg, and each unit represents one 10 mg tablet. Commercial insurers and many state Medicaid programs accept it, while Medicare Part B does not.

The code sits in the S range of the CMS HCPCS Level II code set, the temporary national codes for non-Medicare use. Our HCPCS code library lists the neighboring codes in the same set.

S codes sit in the CMS HCPCS Level II file, but they exist for private payers and Medicaid programs. Medicare does not use them and assigns them no payment rate, which is why S0187 sits outside Medicare Part B.

Clinical context: What tamoxifen is used for

Tamoxifen citrate is a selective estrogen receptor modulator (SERM) with several FDA-approved uses. The supporting diagnosis code changes with the indication, and a mismatch leads straight to a denial.

• Adjuvant treatment of hormone receptor-positive (ER+) breast cancer: The most common use. It is prescribed after surgery, chemotherapy, or radiation to reduce recurrence risk in women and in men with breast cancer.
• Metastatic breast cancer: Used in both male and female patients with ER-positive disease.
• Breast cancer chemoprevention (risk reduction): Approved for high-risk women, with a Gail model 5-year risk of 1.7% or greater. The approval rests on the NSABP P-1 trial. Commercial coverage is narrower here, and prior authorization is more likely.
• Ductal carcinoma in situ (DCIS): Used after surgery to reduce the risk of invasive breast cancer in women with DCIS.

Standard dosing is 20 mg per day, which is two units of S0187. That dosing detail drives the unit count on every claim.

Which payers cover S0187 and which do not

Payer acceptance of S0187 follows the S-code rule, and CMS excludes S codes from Medicare Part B processing. Tamoxifen is an oral drug that Part D formularies cover as a prescription benefit. It is not a physician-administered drug that Part B reimburses. If payer types are new to you, our guide to medical billing basics walks through how each one pays.

Always verify coverage before dispensing. A payer that accepts S codes in general may still decline tamoxifen for the chemoprevention indication. The routing below shows where each claim goes and how the units add up.

How to bill S0187: Units, NDC, and claim form requirements

Accurate billing under S0187 depends on three details at once: the unit count, the NDC, and the place of service. An error in any one of them is enough for the payer to reject the claim.

Step 1: Calculate billing units

One unit of S0187 equals 10 mg of tamoxifen, which is one 10 mg tablet. Bill the total units dispensed, not the number of days supplied. A 20 mg dose is two units.

Worked example: A patient on standard 20 mg/day dosing (two 10 mg tablets) receives a 30-day supply. Total tablets dispensed: 60. Units to bill: 60.

Step 2: Report the 11-digit NDC

Most payers that accept S0187 require the National Drug Code (NDC) on the claim. For electronic 837P claims, the NDC goes in Loop 2410 (Drug Identification), with the unit of measure qualifier set to UN (units).

On a paper CMS-1500, report the NDC in the shaded area of item 24A. Enter the N4 qualifier, then the 11-digit NDC without hyphens in 5-4-2 format, then the unit qualifier UN and the quantity. A clean claim carries the NDC in exactly that format.

Step 3: Select the correct place of service

Use POS 11 (Office) for physician practice dispensing and POS 01 (Pharmacy) for retail or specialty pharmacy billing. Hospital outpatient departments use POS 22 (Outpatient Hospital). The place of service must match the billing provider type, or the payer’s provider-setting edit rejects the claim.

Step 4: Attach supporting diagnosis codes

Include at least one ICD-10-CM diagnosis code that establishes medical necessity. If the diagnosis does not clinically justify tamoxifen, the claim is denied on medical necessity grounds, however correctly S0187 is coded.

Modifiers for S0187 claims

No modifier is standard for S0187. KX and GY are Medicare-defined modifiers, and they apply to an S0187 claim only where a payer’s own policy says so.

Confirm modifier requirements in each payer’s medical policy or EDI companion guide before submitting. A modifier one commercial plan ignores may be a hard edit for another.

Prior authorization requirements for S0187

Prior authorization (PA) requirements for tamoxifen under S0187 vary by payer and by indication. The breast cancer treatment indication generally faces fewer PA hurdles than chemoprevention. Some commercial plans and Medicaid managed care organizations (MCOs) still require PA regardless of indication, particularly for specialty pharmacy dispensing.

When PA is required, payers typically ask for the following documentation.

• ICD-10-CM diagnosis code with clinical notes supporting the indication
• Prescriber NPI
• Pathology or lab results confirming ER-positive status (for cancer treatment indications)
• Gail model risk score documentation (for chemoprevention indications, where the payer asks for it)
• Prior therapy history if step therapy applies
• Treatment plan from the oncologist or prescribing physician

PA requirements are plan-year-specific. A plan that did not require PA last year may add it at contract renewal, so verify at the start of each benefit year.

Common diagnosis codes (ICD-10-CM) paired with S0187

The diagnosis code on a tamoxifen claim tells the payer why the drug is medically necessary. A code that does not clinically support tamoxifen is the fastest route to a medical necessity denial. These ICD-10-CM codes are the ones most often paired with S0187.

Use the most specific code available. Z85.3 alone is sometimes insufficient for a chemoprevention claim, and some payers want Z15.01 or a documented Gail score alongside it. When in doubt, add Z17.0 as a secondary code to confirm ER-positive status.

S0187 vs related codes: How to choose the right one

No tamoxifen-specific J code exists. Oral anticancer J codes do exist, such as J8520 and J8521 for capecitabine and J8999 for oral chemotherapy not otherwise specified. Medicare Part B pays only certain oral anticancer drugs, though, and tamoxifen goes through Part D instead. For commercial payers, S0187 is the code to use.

The CMS HCPCS file carries no 20 mg tamoxifen S code, so S0187 covers every strength in 10 mg units. Bill a 20 mg dose as 2 units of S0187.

Top reasons S0187 claims are denied and how to fix them

S0187 denials cluster around six root causes. Good denial management catches most of them before the claim reaches the payer, and the rework is straightforward when one slips through.

When appealing a medical necessity denial, include a letter of medical necessity from the prescribing oncologist with the pathology report and ICD-10 codes. Appeals that arrive without clinical documentation rarely succeed on first review.

Documentation requirements to support S0187 claims

Solid documentation underpins S0187 reimbursement and is your best defense in a payer audit. A well-built superbill should capture each of these items before the claim goes out.

• Prescription or medication order: Signed by the prescribing clinician, with their NPI, the drug name, strength, quantity, directions, and date ordered.
• Patient diagnosis: ICD-10-CM code(s) with clinical notes confirming the indication. That means a pathology report for cancer treatment, or a Gail score or genetic test results for chemoprevention.
• Quantity dispensed and date of service: Matched exactly to the units billed on the claim.
• NDC of the specific product dispensed: The manufacturer, strength, and package size must match the NDC submitted.
• Prior authorization reference number: If PA was obtained, the approval number goes on the claim. Retain the PA approval documentation per the payer contract and state record-retention rules.
• Pharmacy dispensing record or medication administration record: Confirms the drug was dispensed, and to the correct patient.

Payers auditing tamoxifen claims check three items. They want a diagnosis that supports the drug, a PA reference number where required, and an NDC matching the product billed. A claim missing any of them can trigger recoupment.

How Pabau’s claims management keeps S0187 claims moving

A practice that dispenses tamoxifen usually bills S0187 by hand. Someone keys the NDC, counts the units, and follows the claim through each payer’s portal. A missing qualifier or a wrong unit count often surfaces weeks later as a rejection.

Pabau’s claims management software, which supports insurance billing in the US, submits claims through a clearinghouse and tracks their status. Your team still enters the NDC, the unit qualifier, and the quantity on each claim. Pabau checks the claim for missing details before it goes out.

Every claim then shows its stage, from pending to paid. When a payer rejects a line, the claim is flagged for action with the reason attached. Your biller corrects it and resubmits from one screen.

Track every drug claim through to payment

Pabau’s claims management submits claims through a clearinghouse and tracks each one from pending to paid. Your billing team sees each rejection with its reason and resubmits from one screen.

Book a demo

Conclusion

Before you dispense tamoxifen, decide which route the claim will take. Medicare patients go to Part D by NDC. A commercial or Medicaid claim goes out under S0187 only after you confirm the plan accepts it.

Once the route is settled, most of the risk sits in two fields: the unit count in 10 mg units and the 11-digit NDC. Build both into your claim checklist, and leave modifiers off unless the payer’s policy names one.

Book a demo to see how Pabau tracks each tamoxifen claim from submission to payment.

Continue your research

Need a broader view of medical billing fundamentals? Medical billing overview covers the full claim lifecycle from service capture to payment posting.

Struggling with claim rejection workflows? Denial management in healthcare explains how to build a systematic denial follow-up process.

Want to understand what makes a claim pay first time? Clean claim submission details every element that must be correct before the claim leaves the practice.

Decoding a remittance after an S0187 rejection? Denial codes in medical billing maps common CARC and RARC codes to the right correction.

Frequently asked questions